Independent fund research. Built on SEC filings.

How we research funds

ETF · Large Blend · Roundhill

Roundhill GLP-1 & Weight Loss ETF (OZEM)

Ticker OZEM · Since 2024-05-20 · · Holdings as of Jun 30, 2026

Expense ratio
0.59%$59/yr per $10k
1-yr return
+41.4%as of Dec 2025
Net assets
$54.1Mall share classes
Holdings
26

Bottom line

Is OZEM a good fund? The bottom line

OZEM is an actively managed large blend ETF from Roundhill.

Its expense ratio is 0.59% — about $59 a year on every $10,000 invested, cheaper than 71% of large blend funds we track.

It returned +41.4% over one year (as of Dec 31, 2025, per its prospectus).

With $54.1 million in net assets and 26 holdings, its largest position is Novo Nordisk A/S (13.0%) and the top 10 make up 72% of the portfolio.

What to watch

  • Concentrated: top 10 holdings are 72% of assets

Updated Nov 19, 2026

What OZEM invests in

The Fund seeks to provide capital appreciation.

The Fund is an actively managed exchange-traded fund (ETF) that pursues its investment objective by seeking to provide exposure to companies involved in the development of pharmaceutical drugs and/or supplements that can be utilized to help individuals lose weight, maintain an ideal weight, and/or maintain body composition during weight loss (GLP-1 & Weight Loss Drugs). The Fund will focus its investments in the securities of companies that are the acknowledged leaders in the development of GLP-1 & Weight Loss Drugs, which it defines as those companies that have GLP-1 & Weight Loss Drugs currently undergoing Phase I, Phase II, and/or Phase III of U.S. Food & Drug Administration (FDA) clinical trials and in securities of companies with GLP-1 & Weight Loss Drugs that have been approved by the FDA (GLP-1 & Weight Loss Companies). For non-U.S. companies that are not subject to oversight by…

From the fund's prospectus (filed Apr 30, 2026).

OZEM performance

Fund calendar-year total returns, 2025–2025 2025: +41.4% +41.4% 2025
Fund gain (+)
Average annual total returns
1 yr5 yr10 yr
OZEM+41.4%——
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full OZEM performance history →

What OZEM costs

On a $10,000 investment, OZEM's 0.59% expense ratio costs about $59 a year. The prospectus estimates $738 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full OZEM fee table →

OZEM top 10 holdings

#Holding% of fund
1Novo Nordisk A/S NVO12.96%
2Eli Lilly & Co LLY12.69%
3Mount Vernon Liquid Assets Portfolio, LLC9.93%
4Pfizer Inc PFE6.38%
5Kailera Therapeutics Inc KLRA6.21%
6Viking Therapeutics Inc VKTX5.86%
7CSPC Pharmaceutical Group Ltd 10935.32%
8Chugai Pharmaceutical Co Ltd 45194.51%
9Ascletis Pharma Inc 16724.20%
10Zealand Pharma A/S ZEAL3.92%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 72% of the fund. See all top 25 holdings and asset mix →

Alternatives to OZEM

More funds like OZEM →

OZEM FAQ

What is the expense ratio of OZEM?
OZEM's expense ratio is 0.59%, which works out to about $59 a year for every $10,000 invested. The prospectus estimates total costs of $738 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is OZEM a good investment?
It depends on your goals, but the data points to: concentrated: top 10 holdings are 72% of assets. This is general information, not personalized advice.
What does OZEM hold?
OZEM's largest holdings are Novo Nordisk A/S (13.0%), Eli Lilly & Co (12.7%), Mount Vernon Liquid Assets Portfolio, LLC (9.9%), Pfizer Inc (6.4%), Kailera Therapeutics Inc (6.2%). It holds 26 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
Who manages OZEM?
OZEM is offered by Roundhill through Roundhill ETF Trust.